Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Walgreens Boots Alliance Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Walgreens Boots AllianceDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -41.4% zurückgegangen, während in der Branche Consumer Retailing die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 1.9% pro Jahr.

Wichtige Informationen

-41.4%

Wachstumsrate der Gewinne

-40.3%

EPS-Wachstumsrate

Consumer Retailing Wachstum der Industrie	17.6%
Wachstumsrate der Einnahmen	1.9%
Eigenkapitalrendite	-83.7%
Netto-Marge	-4.2%
Letzte Ertragsaktualisierung	29 Feb 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Walgreens Boots Alliance Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

BMV:WBA * Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
29 Feb 24	144,597	-6,037	25,226
30 Nov 23	142,406	574	24,880
31 Aug 23	139,081	-3,080	24,860
31 May 23	136,108	-3,315	25,073
28 Feb 23	133,291	-3,144	24,502
30 Nov 22	132,184	-2,964	24,912
31 Aug 22	132,703	4,337	24,627
31 May 22	134,516	5,111	25,925
28 Feb 22	135,948	5,926	25,542
30 Nov 21	134,972	5,965	24,865
31 Aug 21	132,509	1,994	23,798
31 May 21	128,617	1,972	23,305
28 Feb 21	124,952	-926	23,194
30 Nov 20	123,509	-981	23,052
31 Aug 20	121,982	179	22,836
31 May 20	125,566	519	23,676
29 Feb 20	129,792	3,339	24,269
30 Nov 19	132,984	3,628	24,521
31 Aug 19	120,074	3,816	23,183
31 May 19	136,354	4,817	25,135
28 Feb 19	136,097	5,133	25,112
30 Nov 18	134,590	5,326	25,065
31 Aug 18	131,537	5,024	24,638
31 May 18	128,244	4,314	23,745
28 Feb 18	124,028	4,134	23,520
30 Nov 17	120,453	3,845	23,067
31 Aug 17	118,214	4,078	23,618
31 May 17	116,701	4,306	23,115
28 Feb 17	116,081	4,247	23,046
30 Nov 16	116,819	4,117	23,302
31 Aug 16	117,351	4,173	23,425
31 May 16	117,237	3,169	23,409
29 Feb 16	116,534	3,368	23,433
30 Nov 15	112,923	4,480	22,996
31 Aug 15	103,444	4,220	21,669
31 May 15	93,979	3,973	20,224
28 Feb 15	84,585	3,385	18,611
30 Nov 14	77,617	2,059	17,661
31 Aug 14	76,392	1,932	17,691
31 May 14	75,276	2,810	17,684
28 Feb 14	74,188	2,720	17,579
30 Nov 13	73,230	2,760	17,473
31 Aug 13	72,217	2,548	17,470

Qualität der Erträge: WBA * ist derzeit unrentabel.

Wachsende Gewinnspanne: WBA * ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: WBA * ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 41.4% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von WBA * verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: WBA * ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Consumer Retailing (15.8%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: WBA * hat eine negative Eigenkapitalrendite (-83.68%), da es derzeit unrentabel ist.

Walgreens Boots Alliance Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Recent updates

Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray

Walgreens Reportedly Contacts Potential Buyers for £7 Billion Boots Drugstore Chain

Second quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

Independent Director recently bought Mex$893k worth of stock

Executive VP & Global CFO recently bought Mex$1.9m worth of stock

New major risk - Financial position

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Upcoming dividend of US$0.25 per share at 4.5% yield

Walgreens Boots Alliance, Inc. Announces Executive Changes

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

Independent Director recently sold Mex$6.0m worth of stock

CEO & Director recently bought Mex$4.1m worth of stock

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on March 12, 2024

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Upcoming dividend of US$0.48 per share at 6.6% yield

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

Insider recently bought Mex$2.5m worth of stock

Third quarter 2023 earnings released: EPS: US$0.14 (vs US$0.33 in 3Q 2022)

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Upcoming dividend of US$0.48 per share at 6.1% yield

CEO & Director recently bought Mex$6.1m worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

Upcoming dividend of US$0.48 per share at 5.2% yield

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

First quarter 2023 earnings released: US$4.31 loss per share (vs US$4.14 profit in 1Q 2022)

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Independent Director recently sold Mex$13m worth of stock

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Full year 2022 earnings released: EPS: US$5.02 (vs US$2.31 in FY 2021)

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. Announces Executive Appointments

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. Names Alethia Jackson Senior Vice President, ESG and Chief DEI Officer

Walgreens Boots Alliance, Inc. Announces Resignation of David J. Brailer as Member of the Board of Directors

Upcoming dividend of US$0.48 per share

Jnd Legal Administration Announces A Class Action Lawsuit in the U.S. District Court for the District of Arizona Against Defendants Theranos, Inc., Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company

Walgreens Boots Alliance Increases Quarterly Dividend, Payable September 9, 2022

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$1.28 in 3Q 2021)

Walgreens Boots Alliance Concludes Strategic Review and Decides to Retain Ownership of Its Successful Boots Business

Walgreens Launches Clinical Trial Business to Address Industrywide Access and Diversity Challenges and Redefine Patient Experience